Anixa Biosciences Inc ANIX:NASDAQ

Last Price$3.09NASDAQ Previous Close - Last Trade as of 4:00PM ET 12/03/21
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$3.01 (3)
Ask (Size)$3.07 (1)
Day Low / HighN/A - N/A
Volume277.1 K

View Biotechnology IndustryPeer Comparison as of 12/03/2021


Anixa Biosciences Inc ( NASDAQ )

Price: $3.09
Change: -0.13 (4.04%)
Volume: 277.1 K
4:00PM ET 12/03/2021

Corbus Pharmaceuticals Holdings Inc ( NASDAQ )

Price: $0.74
Change: -0.08 (10.01%)
Volume: 1.5 M
4:00PM ET 12/03/2021

DiaMedica Therapeutics Inc ( NASDAQ )

Price: $3.43
Change: -0.12 (3.38%)
Volume: 210.8 K
4:00PM ET 12/03/2021

Dyadic International Inc ( NASDAQ )

Price: $3.39
Change: -0.17 (4.78%)
Volume: 83.1 K
4:00PM ET 12/03/2021

X4 Pharmaceuticals Inc ( NASDAQ )

Price: $3.56
Change: -0.46 (11.44%)
Volume: 483.9 K
4:00PM ET 12/03/2021

Read more news Recent News

Anixa Biosciences Starts Dosing Patients in Preventative Breast Cancer Vaccine Study; Shares Rise
2:14PM ET 10/26/2021 MT Newswires

Anixa Biosciences (ANIX) said Tuesday it started dosing patients in a phase 1 study of its investigational vaccine candidate for the prevention of...

Anixa Biosciences Says its CAR-T Cancer Therapy Technology Wins Chinese Patent
9:26AM ET 10/06/2021 MT Newswires

Anixa Biosciences (ANIX) said Wednesday its chimeric antigen receptor-T cell, or CAR-T, cancer treatment technology, has won a patent from the China...

Anixa Biosciences Patent on Cancer Treatment Technology Broadened by USPTO; Shares Down Early
9:46AM ET 10/01/2021 MT Newswires

Anixa Biosciences (ANIX) said Friday that the US Patent and Trademark Office has broadened protection of the biotech company's cancer treatment technology,...

Anixa Gets FDA Clearance for Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
10:15AM ET 8/30/2021 MT Newswires

Anixa Biosciences (ANIX) said Monday the US Food and Drug Administration cleared its investigational new drug application for chimeric antigen receptor-T...

View all Commentary and Analysis

Our First Look At Anixa Biosciences
12:00PM ET 9/23/2021 Seeking Alpha

Company Profile

Business DescriptionAnixa Biosciences, Inc. is a cancer-focused biotechnology company, which focuses on harnessing the body’s immune system in the fight against cancer. It operates through the following segments: Cancer Diagnostics, Cancer Therapeutics, and Legacy Patent Licensing Activities. Cancer Diagnostic segment develops CchekTM platform, a series of inexpensive non-invasive blood tests for the early detection of solid tumors, which is based on the body’s immune response to the presence of a malignancy. Cancer Therapeutics segment offers chimeric antigen receptor T-cell (CAR-T) based immune-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer. The company was founded on November 5, 1982 and is headquartered San Jose, CA. View company web site for more details
Address3150 Almaden Expressway
San Jose, California 95118
Number of Employees8
Recent SEC Filing11/02/20214
Executive Chairman, President & CEOAmit D. Kumar
Secretary, Chief Operating & Financial OfficerMichael J. Catelani
Executive Vice President-DiagnosticsThomas Schlumpberger
Chief Development OfficerPamela D. Garzone

Company Highlights

Price Open$3.25
Previous Close$3.22
52 Week Range$2.49 - 8.09
Market Capitalization$92.5 M
Shares Outstanding29.9 M
SectorHealth Technology
Next Earnings Announcement01/06/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.41
Beta vs. S&P 500N/A
Revenue$1.1 M
Net Profit Margin-2,178.57%
Return on Equity-46.31%

Analyst Ratings as of 06/23/2021

Consensus RecommendationConsensus Icon
Powered by Factset